• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人脐带间充质干细胞辅助治疗1例危重型新型冠状病毒肺炎患者：病例报告

Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report.

作者信息

Zhu Yue, Zhu Rongjia, Liu Kun, Li Xin, Chen Dezhong, Bai Dunyao, Luo Jieli, Liu Yixun, Zhang Yan, Li Li, Hu Junfang, Xu Dayong, Liu Yan, Zhao Robert Chunhua

机构信息

Stem Cell Lab, Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430081, People's Republic of China.

Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, People's Republic of China.

出版信息

Infect Drug Resist. 2020 Sep 28;13:3295-3300. doi: 10.2147/IDR.S272645. eCollection 2020.

DOI:10.2147/IDR.S272645
PMID:33061476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7532065/
Abstract

BACKGROUND

COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available.

CASE PRESENTATION

We reported the treatment process and clinical outcome of a 48-year-old man critically ill COVID-19 patient who received transfusion of allogenic human umbilical cord mesenchymal stem cells (UC-MSCs).

CONCLUSIONS

We proposed that UC-MSC transfusion might be a new option for critically ill COVID-19. Although only one case we were shown, more similar clinical cases are inquired for further evidence providing the potential effectiveness of UC-MSC treatment.

摘要

背景

自2019年12月在中国武汉首次发现新冠病毒病（COVID-19，即2019冠状病毒病）患者以来，它已成为全球突发公共卫生事件。目前，尚无令人满意的抗病毒药物和疫苗。

病例报告

我们报告了一名48岁的COVID-19危重症男性患者接受异体人脐带间充质干细胞（UC-MSCs）输注的治疗过程及临床结果。

结论

我们提出，输注UC-MSCs可能是COVID-19危重症患者的一种新选择。尽管我们仅展示了一例病例，但仍需更多类似临床病例以进一步证明UC-MSCs治疗的潜在有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11eb/7532065/99238b0158c1/IDR-13-3295-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11eb/7532065/4c639379993a/IDR-13-3295-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11eb/7532065/99238b0158c1/IDR-13-3295-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11eb/7532065/4c639379993a/IDR-13-3295-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11eb/7532065/99238b0158c1/IDR-13-3295-g0002.jpg

相似文献

1
Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report.人脐带间充质干细胞辅助治疗1例危重型新型冠状病毒肺炎患者：病例报告
Infect Drug Resist. 2020 Sep 28;13:3295-3300. doi: 10.2147/IDR.S272645. eCollection 2020.
2
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.围生期组织来源的间充质干细胞治疗危重症 COVID-19 诱导的 ARDS 患者：病例系列。
Stem Cell Res Ther. 2021 Jan 29;12(1):91. doi: 10.1186/s13287-021-02165-4.
3
Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report.在一名患有肺纤维化的新冠肺炎危重症患者中输注脐带间充质基质细胞后的免疫调节和抗纤维化作用：一例报告
Front Med (Lausanne). 2021 Nov 17;8:767291. doi: 10.3389/fmed.2021.767291. eCollection 2021.
4
Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey.土耳其 210 例重症和危重症 COVID-19 患者脐带间充质干细胞治疗的临床经验。
Stem Cell Rev Rep. 2021 Oct;17(5):1917-1925. doi: 10.1007/s12015-021-10214-x. Epub 2021 Jul 28.
5
Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).心力衰竭患者静脉输注脐带间充质干细胞的安全性和有效性：一项1/2期随机对照试验（RIMECARD试验[静脉输注脐带间充质干细胞治疗心脏病的随机临床试验]）
Circ Res. 2017 Oct 27;121(10):1192-1204. doi: 10.1161/CIRCRESAHA.117.310712. Epub 2017 Sep 26.
6
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.人脐带间充质干细胞治疗 COVID-19 患者：一项 1 期临床试验。
Signal Transduct Target Ther. 2020 Aug 27;5(1):172. doi: 10.1038/s41392-020-00286-5.
7
Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient.脐带血来源的间充质干细胞治疗一名危重症新型冠状病毒肺炎患者
J Infect Dev Ctries. 2020 Oct 31;14(10):1138-1145. doi: 10.3855/jidc.13081.
8
COVID-19 disease treatment: pivotal challenges in the arena of umbilical cord-mesenchymal stem cells (UC-MSCs).新型冠状病毒肺炎的治疗：脐带间充质干细胞领域的关键挑战
Front Cell Dev Biol. 2023 May 19;11:1146835. doi: 10.3389/fcell.2023.1146835. eCollection 2023.
9
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).用于治疗新冠肺炎急性呼吸窘迫综合征（ARDS）患者的脐带间充质干细胞
CellR4 Repair Replace Regen Reprogram. 2020;8. doi: 10.32113/cellr4_20204_2839. Epub 2020 Apr 28.
10
The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice.人脐带间充质干细胞的归巢及其对 2 型糖尿病小鼠巨噬细胞极化的后续调节。
Int Immunopharmacol. 2018 Jul;60:235-245. doi: 10.1016/j.intimp.2018.04.051. Epub 2018 May 25.

引用本文的文献

1
Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.间充质干细胞治疗 COVID-19 的临床试验。
Curr Stem Cell Res Ther. 2024;19(8):1055-1071. doi: 10.2174/011574888X260032230925052240.
2
Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.应对新冠疫情时代的挑战：从标准治疗到脐带间充质干细胞的新治疗策略。
Cells. 2023 Jun 19;12(12):1664. doi: 10.3390/cells12121664.
3
Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.

本文引用的文献

1
Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?间充质基质细胞及其分泌的细胞外囊泡是否可作为治疗 COVID-19 肺炎的工具？
J Control Release. 2020 Sep 10;325:135-140. doi: 10.1016/j.jconrel.2020.06.036. Epub 2020 Jul 3.
2
Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use.间充质基质细胞分泌组治疗严重 COVID-19 感染：治疗用途的前提。
Cells. 2020 Apr 9;9(4):924. doi: 10.3390/cells9040924.
3
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.
系统评价和荟萃分析间充质基质/干细胞作为 COVID-19 治疗的策略手段。
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231158276. doi: 10.1177/17534666231158276.
4
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review.间充质干细胞疗法治疗新型冠状病毒肺炎患者的临床疗效分析：一项系统评价
World J Clin Cases. 2022 Sep 26;10(27):9714-9726. doi: 10.12998/wjcc.v10.i27.9714.
5
Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.间充质干细胞治疗重症 COVID-19 的疗效：文献分析与病例研究。
Stem Cells Transl Med. 2022 Nov 18;11(11):1103-1112. doi: 10.1093/stcltm/szac067.
6
Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment.间充质干细胞及其衍生的小细胞外囊泡在 COVID-19 治疗中的应用。
Stem Cell Res Ther. 2022 Aug 12;13(1):410. doi: 10.1186/s13287-022-03034-4.
7
Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.MSC 细胞疗法治疗 COVID-19 住院患者的疗效和安全性：系统评价和荟萃分析。
Stem Cells Transl Med. 2022 Jul 20;11(7):688-703. doi: 10.1093/stcltm/szac032.
8
Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.间充质基质细胞治疗 COVID-19 相关 ARDS：一项多中心随机双盲试验。
Crit Care. 2022 Feb 21;26(1):48. doi: 10.1186/s13054-022-03930-4.
9
SARS-CoV-2 Infection and Lung Regeneration.SARS-CoV-2 感染与肺再生。
Clin Microbiol Rev. 2022 Apr 20;35(2):e0018821. doi: 10.1128/cmr.00188-21. Epub 2022 Feb 2.
10
Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report.在一名患有肺纤维化的新冠肺炎危重症患者中输注脐带间充质基质细胞后的免疫调节和抗纤维化作用：一例报告
Front Med (Lausanne). 2021 Nov 17;8:767291. doi: 10.3389/fmed.2021.767291. eCollection 2021.
新型冠状病毒在武汉持续爆发中的进化及其刺突蛋白对人类传播风险的建模。
Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21.
4
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.一种在中国出现的新型冠状病毒——影响评估的关键问题
N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24.
7
Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through "pharmaceuticalization" for the best formulation.间质干细胞/基质细胞 secretome 用于肺再生：为了最佳配方而经历漫长的“药物化”之路。
J Control Release. 2019 Sep 10;309:11-24. doi: 10.1016/j.jconrel.2019.07.022. Epub 2019 Jul 18.
8
ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.ACE2 通过抑制 VEGFa/VEGFR2/ERK 通路抑制乳腺癌血管生成。
J Exp Clin Cancer Res. 2019 Apr 25;38(1):173. doi: 10.1186/s13046-019-1156-5.
9
Reversibly immortalized human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are responsive to BMP9-induced osteogenic and adipogenic differentiation.可重编程的人脐带间充质干细胞（UC-MSCs）对 BMP9 诱导的成骨和成脂分化有反应。
J Cell Biochem. 2018 Nov;119(11):8872-8886. doi: 10.1002/jcb.27140. Epub 2018 Aug 4.
10
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis.间充质基质细胞疗法治疗类固醇难治性急性移植物抗宿主病后的生存率：系统评价和荟萃分析。
Lancet Haematol. 2016 Jan;3(1):e45-52. doi: 10.1016/S2352-3026(15)00224-0. Epub 2015 Nov 27.